Related Experiment Video
Updated: Feb 10, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies
Ian F Caplan1, Kathleen A Maguire-Zeiss1,2
1Biology Department, Georgetown University, Washington, DC, United States.
Abstract:
The innate immune response in the central nervous system (CNS) is implicated as both beneficial and detrimental to health. Integral to this process are microglia, the resident immune cells of the CNS. Microglia express a wide variety of pattern-recognition receptors, such as Toll-like receptors, that detect changes in the neural environment. The activation of microglia and the subsequent proinflammatory response has become increasingly relevant to synucleinopathies, including Parkinson's disease the second most prevalent neurodegenerative disease. Within these diseases there is evidence of the accumulation of endogenous α-synuclein that stimulates an inflammatory response from microglia via the Toll-like receptors. There have been recent developments in both new and old pharmacological agents designed to target microglia and curtail the inflammatory environment. This review will aim to delineate the process of microglia-mediated inflammation and new therapeutic avenues to manage the response.
Insights
Microglia, the brain's immune cells, drive inflammation in neurodegenerative diseases like Parkinson's. Targeting microglial Toll-like receptors offers new therapeutic strategies for these conditions.
Area of Science:
- Neuroimmunology
- Central Nervous System (CNS) Immunity
- Neuroinflammation
Background:
- Microglia are the resident immune cells of the CNS, playing a dual role in health and disease.
- They express pattern-recognition receptors, including Toll-like receptors (TLRs), which detect neural environment changes.
- Microglia-mediated inflammation is increasingly recognized in synucleinopathies, such as Parkinson's disease.
Purpose of the Study:
- To delineate the mechanisms of microglia-mediated inflammation in the CNS.
- To explore the role of alpha-synuclein in activating microglial inflammatory responses via TLRs.
- To review emerging pharmacological strategies targeting microglia for neurodegenerative diseases.
Main Methods:
- Review of current literature on neuroinflammation and microglia.
- Analysis of the role of alpha-synuclein in activating microglial pathways.
- Examination of pharmacological agents targeting microglial inflammatory responses.
Main Results:
- Endogenous alpha-synuclein accumulation stimulates microglial inflammatory responses through TLRs in synucleinopathies.
- Microglia activation contributes to the pathogenesis of Parkinson's disease.
- Novel therapeutic agents are being developed to modulate microglial activity.
Conclusions:
- Microglia play a critical role in the inflammatory processes underlying neurodegenerative diseases like Parkinson's.
- Targeting microglial activation pathways, particularly via TLRs, presents a promising therapeutic avenue.
- Further research into modulating the neuroinflammatory environment is crucial for managing synucleinopathies.
Related Concept Videos
Signal Sequences and Sorting Receptors
Insulin: The Receptor and Signaling Pathways
Internal Receptors
Endocrine Signaling
Yeast Signaling
Synaptic Signaling

